Onco-hematology
NCCN Guideline: T-Cell Lymphomas.
15 Mar, 2022 | 08:41h | UTC
Safety and efficacy of antibiotic de-escalation and discontinuation in high-risk hematological patients with febrile neutropenia: a single-center experience.
10 Mar, 2022 | 10:09h | UTCRelated: Management of febrile neutropaenia: ESMO Clinical Practice Guidelines – Annals of Oncology
Commentary on Twitter
OFID: In high-risk hematological patients w/ febrile neutropenia, antibiotic de-escalation and discontinuation prior to neutrophil recovery did not lead to an increase in infectious complications. https://t.co/eUer1fmoc6 #IDSAJournals @PaulSaxMD @DrJLi @FungalDoc @jobadd pic.twitter.com/HuGRYA8YW3
— IDSA (@IDSAInfo) January 5, 2022
Review: Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies.
9 Mar, 2022 | 08:35h | UTC
M-A: Efficacy of covid-19 vaccines in immunocompromised patients.
4 Mar, 2022 | 10:01h | UTCNews Release: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom
Related: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
Commentary on Twitter
NEW RESEARCH: Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, suggests new research https://t.co/l2IWfSb0zd @sundar__raghav
— The BMJ (@bmj_latest) March 3, 2022
Guideline: Management of Clostridioides difficile infection in hematopoietic cell transplant recipients.
3 Mar, 2022 | 08:17h | UTCSee other articles in the series:
SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients.
2 Mar, 2022 | 08:51h | UTC
Review: Cancer-associated venous thromboembolism.
21 Feb, 2022 | 08:42h | UTCCancer-associated venous thromboembolism – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Related:
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.
Isatuximab plus pomalidomide and low-dose dexamethasone vs. pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
21 Feb, 2022 | 08:13h | UTCIsatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study – The Lancet Oncology (link to abstract – $ for full-text)
Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
16 Feb, 2022 | 10:13h | UTC
Commentary on Twitter
A review of the 23 studies of Covid vaccination for immunocompromised people indicates the level of responders varies with conditions. Even additional doses may not provide sufficient protection for some, requiring additional measureshttps://t.co/BjaKrJUAbO @LancetGH pic.twitter.com/EYVWAX23Ig
— Eric Topol (@EricTopol) February 15, 2022
Australasian Consensus Guidelines for the use of antifungal agents in the hematology-oncology setting.
9 Feb, 2022 | 08:49h | UTCConsensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021
Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021
Expert Consensus: Treatment algorithm in cancer-associated thrombosis.
9 Feb, 2022 | 08:42h | UTC
Review: Diagnosis and Management of Multiple Myeloma.
2 Feb, 2022 | 08:11h | UTCDiagnosis and Management of Multiple Myeloma: A Review – JAMA (free for a limited period)
Audio Clinical Review: Diagnosis and Management of Multiple Myeloma – JAMA
RCT: Olanzapine may improve the control of vomiting in the delayed phase in children receiving highly emetogenic chemotherapy.
30 Jan, 2022 | 14:13h | UTCEfficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial – Journal of Pediatric Hematology/Oncology (link to abstract – $ for full-text)
Guideline Summary: Management of the top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.
30 Jan, 2022 | 14:11h | UTCOriginal Article: ASCO Guideline Update: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.
Related:
Clinical practice guideline on immune checkpoint inhibitor-related adverse events.
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (several resources on the subject)
RCT: Axicabtagene Ciloleucel as second-line therapy for Large B-Cell Lymphoma.
30 Jan, 2022 | 13:41h | UTC
Commentary on Twitter
In a trial involving patients with relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to significantly longer event-free survival than standard salvage chemotherapy. #ASH21 https://t.co/V1WfVJ2k9V pic.twitter.com/ZHUhx8es27
— NEJM (@NEJM) December 11, 2021
RCT: In patients with chronic myeloid leukemia in chronic phase resistant/intolerant to ≥2 tyrosine kinase inhibitors, Asciminib resulted in better disease response compared to Bosutinib.
28 Jan, 2022 | 08:00h | UTCNews Release: Asciminib Superior to Bosutinib in Chronic-Phase CML – ASH Clinical News
RCT: In patients with previously untreated Diffuse Large B-Cell Lymphoma, a modified regimen of R-CHOP (pola-R-CHP), in which vincristine was replaced with polatuzumab, was associated with improved outcomes compared to standard R-CHOP treatment.
21 Jan, 2022 | 09:28h | UTCPolatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
A single-arm study evaluated Naive T-Cell depleted peripheral blood stem-cell grafts for the prevention of chronic graft-versus-host disease.
19 Jan, 2022 | 08:22h | UTCNaive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease – Journal of Clinical Oncology
Commentary: New graft strategy may improve outcomes for blood stem cell recipients – University of Pittsburg
Prolonged follow-up of RCT: Emission Tomography–driven strategy in advanced Hodgkin Lymphoma.
19 Jan, 2022 | 08:16h | UTCPositron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
RCT: Sirolimus plus prednisolone vs. sirolimus monotherapy for kaposiform hemangioendothelioma.
18 Jan, 2022 | 09:08h | UTCSirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial – Blood (link to abstract – $ for full-text)
Best Practice Recommendations: Management of adults and children receiving CAR T-cell therapy.
12 Jan, 2022 | 08:31h | UTC
Hematology, the ASH Education Program – series of review articles with clinical cases published annually by the American Society of Hematology.
13 Dec, 2021 | 08:45h | UTCHomepage: Hematology, the ASH Education Program
Non-inferiority randomized trial showed radiotherapy can be safely omitted in many children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma.
10 Dec, 2021 | 10:04h | UTC
RCT: Maribavir for refractory Cytomegalovirus infections with or without resistance post-transplant.
7 Dec, 2021 | 08:37h | UTC
Review: Castleman disease.
26 Nov, 2021 | 09:49h | UTCCastleman disease – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Castleman Disease (if the link is paywalled, try this one)